Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis

Approximately 12–13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough evaluation. A recent Phase 2 study (NCT03099187) described a significant effect of pirfenidone vs. placebo on forced vital capacity (FVC) measured by site spirom...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina-Molina, Maria, Kreuter, Michael, Cottin, Vincent, Corte, Tamera J., Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Axmann, Judit, Maher, Toby M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247211/
https://www.ncbi.nlm.nih.gov/pubmed/35783648
http://dx.doi.org/10.3389/fmed.2022.897102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247211/
https://www.ncbi.nlm.nih.gov/pubmed/35783648
http://dx.doi.org/10.3389/fmed.2022.897102

Ejemplares similares